Pub Date : 2016-05-23DOI: 10.4172/2329-6771.1000169
Nattamol Hosiriluck, Catherine Jones
Introduction: Basal cell carcinoma accounts for 80% of all non-melanoma skin cancer. Vismodegib is the hedgehog signaling pathway inhibitor, which has shown improved outcome in both locally advanced and metastatic basal cell carcinoma. There are, however, reports of cutaneous squamous cell carcinomas developing while on active treatment with vismodegib. We present a case of transition to squamous cell carcinoma after vismodegib treatment in a patient with a 10-year history of basal cell carcinoma. Case presentation: 44-year-old Caucasian man with 10 year history of basal cell carcinoma on his left chest wall and left shoulder was treated with local resection and actively on vismodegib. He presented with enlarging and infected mass. He underwent left forequarter amputation of his left arm, shoulder and clavicle. Pathology reported basosquamous cell carcinoma with scapula invasion and axillary lymph node metastases. Staging was stage III T4N1M0. He continued on vismodegib post-operation. Three months after his amputation, the patient presented with a recurrent left shoulder mass with nonhealing surgical wound. Imaging revealed vascular invasion. Biopsy of the lesion was consistent with invasive squamous cell carcinoma with genomic profiling of PIK3R1, PTCH1 and STK11 gene mutations. At the patient’s request he was subsequently transferred to another facility for a second surgical opinion. Conclusion: Biopsy and genetic analyses of basal cell carcinoma lesions should be considered in every case that has treatment plan for hedgehog signaling pathway inhibitor to evaluate for potential secondary squamous cell carcinoma growth. Further study is needed to confirm the mechanism of basal cell resistance to anti-smoothened therapy and eventual squamous cell carcinoma growth.
{"title":"Emergence of Squamous Cell Carcinoma during Treatment of Basal Cell Carcinoma with Vismodegib","authors":"Nattamol Hosiriluck, Catherine Jones","doi":"10.4172/2329-6771.1000169","DOIUrl":"https://doi.org/10.4172/2329-6771.1000169","url":null,"abstract":"Introduction: Basal cell carcinoma accounts for 80% of all non-melanoma skin cancer. Vismodegib is the hedgehog signaling pathway inhibitor, which has shown improved outcome in both locally advanced and metastatic basal cell carcinoma. There are, however, reports of cutaneous squamous cell carcinomas developing while on active treatment with vismodegib. We present a case of transition to squamous cell carcinoma after vismodegib treatment in a patient with a 10-year history of basal cell carcinoma. \u0000Case presentation: 44-year-old Caucasian man with 10 year history of basal cell carcinoma on his left chest wall and left shoulder was treated with local resection and actively on vismodegib. He presented with enlarging and infected mass. He underwent left forequarter amputation of his left arm, shoulder and clavicle. Pathology reported basosquamous cell carcinoma with scapula invasion and axillary lymph node metastases. Staging was stage III T4N1M0. He continued on vismodegib post-operation. Three months after his amputation, the patient presented with a recurrent left shoulder mass with nonhealing surgical wound. Imaging revealed vascular invasion. Biopsy of the lesion was consistent with invasive squamous cell carcinoma with genomic profiling of PIK3R1, PTCH1 and STK11 gene mutations. At the patient’s request he was subsequently transferred to another facility for a second surgical opinion. \u0000Conclusion: Biopsy and genetic analyses of basal cell carcinoma lesions should be considered in every case that has treatment plan for hedgehog signaling pathway inhibitor to evaluate for potential secondary squamous cell carcinoma growth. Further study is needed to confirm the mechanism of basal cell resistance to anti-smoothened therapy and eventual squamous cell carcinoma growth.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"10 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2016-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87776343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-05-18DOI: 10.4172/2329-6771.1000168
A. Ruzzenente, F. Bagante, Marco Sandri Bs, C. Pedrazzani, M. Brunelli, T. Campagnaro, S. Conci, P. Capelli, A. Guglielmi, A. Scarpa, C. Iacono
Recurrence after liver surgery for hepatocellular carcinoma (HCC) remains the major dismal event affecting patient’s overall survival (OS). Several studies on gene signature showed an association between MYC deregulation and poor prognosis. We aimed to analyze prognostic factors, including MYC status, for disease free survival (DFS) and OS, as well as to develop a new prognostic model for HCC able to predict the patient’s prognosis. Methods: Sixty-three patients who underwent liver resection for HCC from January 2006 to December 2009 in a single division of the Department of Surgery at the University of Verona were included into this study. Predictors of DFS and OS were identified using univariate and multivariate survival analysis. The prognostic ability of our model was compared using Harrell’s c-index to current clinical staging systems (AJCC/TNM 7th ed., BCLC and CLIP). Results: Predictors of DFS, in both univariate and multivariable analysis were number of HCC, serum AFP, and MYC status; these variables were included in a nomogram to predict DFS. Patients were classified into two groups (high- and low-risk group) according to their predicted 12-month risk of recurrence. Patients in low-risk group showed a 36-month DFS of 43% compared to 0% for high-risk group. Furthermore, patients in low-risk group presented a 36-month OS of 70% compared to 15% for high-risk group. Our model was included in AJCC/TNM 7th ed., BCLC and CLIP staging systems. When reclassified with our model, CLIP presented the highest predictive ability (c-index=73%) compared to the others staging-systems. Conclusions: We developed a prognostic model for DFS after hepatectomy for HCC, based on MYC gene status and clinical features (number of nodules and AFP serum level). Our new prognostic model could have important clinical applications in selecting those patients who might have major benefits from surgical resection.
{"title":"A Novel Prognostic Score based on Serum Alpha-Fetoprotein, Number of Nodules, and MYC Gene Status Predicts Prognosis of Patients after Liver Resection for Hepatocellular Carcinoma","authors":"A. Ruzzenente, F. Bagante, Marco Sandri Bs, C. Pedrazzani, M. Brunelli, T. Campagnaro, S. Conci, P. Capelli, A. Guglielmi, A. Scarpa, C. Iacono","doi":"10.4172/2329-6771.1000168","DOIUrl":"https://doi.org/10.4172/2329-6771.1000168","url":null,"abstract":"Recurrence after liver surgery for hepatocellular carcinoma (HCC) remains the major dismal event affecting patient’s overall survival (OS). Several studies on gene signature showed an association between MYC deregulation and poor prognosis. We aimed to analyze prognostic factors, including MYC status, for disease free survival (DFS) and OS, as well as to develop a new prognostic model for HCC able to predict the patient’s prognosis. Methods: Sixty-three patients who underwent liver resection for HCC from January 2006 to December 2009 in a single division of the Department of Surgery at the University of Verona were included into this study. Predictors of DFS and OS were identified using univariate and multivariate survival analysis. The prognostic ability of our model was compared using Harrell’s c-index to current clinical staging systems (AJCC/TNM 7th ed., BCLC and CLIP). Results: Predictors of DFS, in both univariate and multivariable analysis were number of HCC, serum AFP, and MYC status; these variables were included in a nomogram to predict DFS. Patients were classified into two groups (high- and low-risk group) according to their predicted 12-month risk of recurrence. Patients in low-risk group showed a 36-month DFS of 43% compared to 0% for high-risk group. Furthermore, patients in low-risk group presented a 36-month OS of 70% compared to 15% for high-risk group. Our model was included in AJCC/TNM 7th ed., BCLC and CLIP staging systems. When reclassified with our model, CLIP presented the highest predictive ability (c-index=73%) compared to the others staging-systems. Conclusions: We developed a prognostic model for DFS after hepatectomy for HCC, based on MYC gene status and clinical features (number of nodules and AFP serum level). Our new prognostic model could have important clinical applications in selecting those patients who might have major benefits from surgical resection.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"1 1","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2016-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87368627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-05-14DOI: 10.4172/2329-6771.1000167
Y. Yonemura, E. Canbay, S. Sako, H. Ishibashi, M. Hirano, A. Mizumoto, Kousuke Noguchi, N. Takao, M. Ichinose, Gorou Tsukiyama, Yang Liu, S. Fushida
Background and objective: The aim of this study is to analyze anatomical distribution, timing and outcomes of recurrence after complete cytoreduction and perioperative chemotherapy for peritoneal metastasis from gastric cancer (GCPM). Method: Data of 193 GCPM patients who underwent a complete cytoreductive surgery (CRS) after treatment with neoadjuvant chemotherapy were entered into a prospective database and the recurrence was analyzed. Result: The median time to progression was 16.2 months, median overall survival (OS) was 21.6 months and 5-year survival rate was 18.1%. Five years after CRS, 11 patients were disease free survivors. Recurrence rate was 68.5% (126/184). Mutivariate analysis confirmed small bowel peritoneal cancer index of ≥3 and pathologic nonresponders after NAC as independent risk factors for recurrence. Patients were treated with systemic chemotherapy or second cytoreductive surgery for recurrence. However, survival after diagnosis of recurrence was poor with median survival of 2.9 months. The most common type of recurrence was diffuse peritoneal recurrence (71%, 90/126). Localized intra-abdominal recurrence was experienced in only 7 patients. Conclusion: Pathologic non-responders and small bowel PCI of ≥3 are independent risk factors for recurrence. Exploratory laparoscopy after NAC might be a useful strategy for the selection of patients for CRS.
{"title":"Risk Factors for Recurrence after Complete Cytoreductive Surgery and Perioperative Chemotherapy in Peritoneal Metastases from Gastric Cancer","authors":"Y. Yonemura, E. Canbay, S. Sako, H. Ishibashi, M. Hirano, A. Mizumoto, Kousuke Noguchi, N. Takao, M. Ichinose, Gorou Tsukiyama, Yang Liu, S. Fushida","doi":"10.4172/2329-6771.1000167","DOIUrl":"https://doi.org/10.4172/2329-6771.1000167","url":null,"abstract":"Background and objective: The aim of this study is to analyze anatomical distribution, timing and outcomes of recurrence after complete cytoreduction and perioperative chemotherapy for peritoneal metastasis from gastric cancer (GCPM). Method: Data of 193 GCPM patients who underwent a complete cytoreductive surgery (CRS) after treatment with neoadjuvant chemotherapy were entered into a prospective database and the recurrence was analyzed. Result: The median time to progression was 16.2 months, median overall survival (OS) was 21.6 months and 5-year survival rate was 18.1%. Five years after CRS, 11 patients were disease free survivors. Recurrence rate was 68.5% (126/184). Mutivariate analysis confirmed small bowel peritoneal cancer index of ≥3 and pathologic nonresponders after NAC as independent risk factors for recurrence. Patients were treated with systemic chemotherapy or second cytoreductive surgery for recurrence. However, survival after diagnosis of recurrence was poor with median survival of 2.9 months. The most common type of recurrence was diffuse peritoneal recurrence (71%, 90/126). Localized intra-abdominal recurrence was experienced in only 7 patients. Conclusion: Pathologic non-responders and small bowel PCI of ≥3 are independent risk factors for recurrence. Exploratory laparoscopy after NAC might be a useful strategy for the selection of patients for CRS.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"22 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2016-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75815409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-05-13DOI: 10.4172/2329-6771.1000166
F. Recchia, G. Candeloro, S. Rea
Oxaliplatin (LOHP) and pegylated liposomal doxorubicin (PLD) are active single agents in recurrent ovarian cancer (ROC). In this phase II study we explored safety and activity of combined LOHP and PLD in the treatment of ROC. Eligible patients had had disease recurrence following a paclitaxel/ carboplatin regimen or following cisplatinum or non-platinum-based second line chemotherapy. Other eligibility criteria were a performance status ≤ 2 and a life expectancy > 3 months. Treatment consisted of 120 mg/m2 LOHP and 40 mg/m2 PLD, given over 2 days, every 3 weeks. Forty-six patients with ROC were entered into the study between 10/2001 and 10/2005; 67.5% of patients were platinum-sensitive. Toxicity was moderate, with grade 3 or 4 neutropenia in 2% of patients, and grade 2 PPE in 7% of patients. Overall response rate was 67.5%. Median progression-free survival (PFS) was 27.5 months, while median overall survival was 44 months. We conclude that LOHP and PLD are active in ROC, and can be safely administered in pre-treated patients
{"title":"Long-term Follow-up of Pegylated Liposomal Doxorubicin and Oxaliplatin in Recurrent Ovarian Cancer","authors":"F. Recchia, G. Candeloro, S. Rea","doi":"10.4172/2329-6771.1000166","DOIUrl":"https://doi.org/10.4172/2329-6771.1000166","url":null,"abstract":"Oxaliplatin (LOHP) and pegylated liposomal doxorubicin (PLD) are active single agents in recurrent ovarian cancer (ROC). In this phase II study we explored safety and activity of combined LOHP and PLD in the treatment of ROC. Eligible patients had had disease recurrence following a paclitaxel/ carboplatin regimen or following cisplatinum or non-platinum-based second line chemotherapy. Other eligibility criteria were a performance status ≤ 2 and a life expectancy > 3 months. Treatment consisted of 120 mg/m2 LOHP and 40 mg/m2 PLD, given over 2 days, every 3 weeks. Forty-six patients with ROC were entered into the study between 10/2001 and 10/2005; 67.5% of patients were platinum-sensitive. Toxicity was moderate, with grade 3 or 4 neutropenia in 2% of patients, and grade 2 PPE in 7% of patients. Overall response rate was 67.5%. Median progression-free survival (PFS) was 27.5 months, while median overall survival was 44 months. We conclude that LOHP and PLD are active in ROC, and can be safely administered in pre-treated patients","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"31 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2016-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87320019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-05-09DOI: 10.4172/2329-6771.1000165
Supreeth Nekkanti, C. Vijay, S. Theja, Rajashree Ravishankar, Anubhav Verma
We report a 70 year old retired male leading a sedentary lifestyle, who had presented to us with deformity of his left knee (Figure 1). The authors took a detailed history and traced that he had a history of fall 10 years back and suffered an injury to his left knee. He didn’t undergo any medical or surgical treatment for the same. He has been doing all his daily activities and work normally since then. Clinical examination revealed that there was no bony tenderness and had complete range of movements of his knee joint (Figure 2). Radiograph of his knee joint showed an old widely displaced two-part patella fracture (Figure 3). The possible explanation for his complete lack of symptoms and complete range of movements of the knee is due to development of pseudoarthosis of the patella.
{"title":"An Unusual Presentation of Non Union of Patella with Full Range of Movements of the Knee Joint","authors":"Supreeth Nekkanti, C. Vijay, S. Theja, Rajashree Ravishankar, Anubhav Verma","doi":"10.4172/2329-6771.1000165","DOIUrl":"https://doi.org/10.4172/2329-6771.1000165","url":null,"abstract":"We report a 70 year old retired male leading a sedentary lifestyle, who had presented to us with deformity of his left knee (Figure 1). The authors took a detailed history and traced that he had a history of fall 10 years back and suffered an injury to his left knee. He didn’t undergo any medical or surgical treatment for the same. He has been doing all his daily activities and work normally since then. Clinical examination revealed that there was no bony tenderness and had complete range of movements of his knee joint (Figure 2). Radiograph of his knee joint showed an old widely displaced two-part patella fracture (Figure 3). The possible explanation for his complete lack of symptoms and complete range of movements of the knee is due to development of pseudoarthosis of the patella.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"10 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91440037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-05-06DOI: 10.4172/2329-6771.1000164
W. Qun, Y. Tao, D. Yi, Lou Weijun, W. Fu, Chang Bo
Background: Hepatic carcinoma (HCC) has rised in China because of hepatitis B virus(HBV) effection, it has been famous for devastating malignancy as well as little treatment effect for HCC Sorafenib, has been successfully applied for solid tumors such as renal cancer, hepatocellular carcinoma. Sorafenib used alone or combination with others can induce growth-inhibition and apoptosis in vitro experiment. Sorafenib now was suggested to advanced hepatic carcinoma patient unqualitied for hepatectomy and transplant. Methods: A team of advanced hepatic carcinoma patients were enrolled for Sorafenib monotherapy or combination with HIAC,TACE, systemtic chemotherapy with arsenic trioxide and octreotide on base of personal disease progress CT and level of AFP were used to assess the tumor effect for decision of next treatment plan, An individualization treatment plan was performed ultimately. Result: Patients of initially HCC were extended survival time by Sorafenib monotherapy or combination with HIAC and TACE. TACE made hepatic lesion stable, added therapy of arsenic trioxide could be able to make TACErefractory and lung metatasis lesion under control. Conclusion: Sorafenib monotherapy or combination with others added therapy on needs of patients personal disease progress can extend survival time. Sorafenib applied individually may be more effective.
{"title":"Effective Personalized Treatment of Advanced Hepatic Carcinoma basedon Sorafenib","authors":"W. Qun, Y. Tao, D. Yi, Lou Weijun, W. Fu, Chang Bo","doi":"10.4172/2329-6771.1000164","DOIUrl":"https://doi.org/10.4172/2329-6771.1000164","url":null,"abstract":"Background: Hepatic carcinoma (HCC) has rised in China because of hepatitis B virus(HBV) effection, it has been famous for devastating malignancy as well as little treatment effect for HCC Sorafenib, has been successfully applied for solid tumors such as renal cancer, hepatocellular carcinoma. Sorafenib used alone or combination with others can induce growth-inhibition and apoptosis in vitro experiment. Sorafenib now was suggested to advanced hepatic carcinoma patient unqualitied for hepatectomy and transplant. Methods: A team of advanced hepatic carcinoma patients were enrolled for Sorafenib monotherapy or combination with HIAC,TACE, systemtic chemotherapy with arsenic trioxide and octreotide on base of personal disease progress CT and level of AFP were used to assess the tumor effect for decision of next treatment plan, An individualization treatment plan was performed ultimately. Result: Patients of initially HCC were extended survival time by Sorafenib monotherapy or combination with HIAC and TACE. TACE made hepatic lesion stable, added therapy of arsenic trioxide could be able to make TACErefractory and lung metatasis lesion under control. Conclusion: Sorafenib monotherapy or combination with others added therapy on needs of patients personal disease progress can extend survival time. Sorafenib applied individually may be more effective.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85921260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-04-11DOI: 10.4172/2329-6771.1000162
A. Couderc, B. Coutanceau, R. Mouawad, B. Mugnier, A. Chebib, É. Baudry, J. Spinelli, L. Battaglia, P. Chaibi
Introduction and objectives: The incidence of multiple myeloma (MM) increases with age. There is a clear decrease in overall survival (OS) in older patients. The purpose of this study was to investigate prognostic factors of MM in this population. Materials and methods: This is an analytic prospective single-center study conducted over 27 months including MM elderly patients treated with weekly subcutaneous bortezomib alone or associated with another chemotherapy. Results: Our work has included 45 patients (median age 84.3 years). Most of them (77.7%) had a PS ≥ 2, 75.6% were undernourished and 57, 1% had a Mini Mental State Examination (MMSE)<26. Haematological grade 3 toxicities were observed in 11% of patients. After 17 months mean follow-up, the median of OS was 18.6 months. In univariate analysis, significant predictors for OS were instrumental activities of daily living (IADL) ≥ 2 (p = 0.003), activities of daily living (ADL)<5 (p = 0.005), the body mass index (BMI)<21 (p = 0.03) and using hospitalization at home unit for bortezomib injections (p = 0.01). In multivariate analysis, significant predictors for OS were ADL<5 (p = 0.005), using hospitalization at home unit (p = 0.007) and IADL ≥ 2 (p = 0.05) Conclusion: In our work, weekly subcutaneous bortezomib was well tolerated. We have shown that functional decline, malnutrition and hospitalization at home unit are predictors of OS. These results lead us to reflect on the need to include these factors in the choice of treatment in elderly patients with MM.
{"title":"Prognostic Factors in Elderly Patients with Multiple Myeloma Treatedwith Weekly Bortezomib","authors":"A. Couderc, B. Coutanceau, R. Mouawad, B. Mugnier, A. Chebib, É. Baudry, J. Spinelli, L. Battaglia, P. Chaibi","doi":"10.4172/2329-6771.1000162","DOIUrl":"https://doi.org/10.4172/2329-6771.1000162","url":null,"abstract":"Introduction and objectives: The incidence of multiple myeloma (MM) increases with age. There is a clear decrease in overall survival (OS) in older patients. The purpose of this study was to investigate prognostic factors of MM in this population. Materials and methods: This is an analytic prospective single-center study conducted over 27 months including MM elderly patients treated with weekly subcutaneous bortezomib alone or associated with another chemotherapy. Results: Our work has included 45 patients (median age 84.3 years). Most of them (77.7%) had a PS ≥ 2, 75.6% were undernourished and 57, 1% had a Mini Mental State Examination (MMSE)<26. Haematological grade 3 toxicities were observed in 11% of patients. After 17 months mean follow-up, the median of OS was 18.6 months. In univariate analysis, significant predictors for OS were instrumental activities of daily living (IADL) ≥ 2 (p = 0.003), activities of daily living (ADL)<5 (p = 0.005), the body mass index (BMI)<21 (p = 0.03) and using hospitalization at home unit for bortezomib injections (p = 0.01). In multivariate analysis, significant predictors for OS were ADL<5 (p = 0.005), using hospitalization at home unit (p = 0.007) and IADL ≥ 2 (p = 0.05) Conclusion: In our work, weekly subcutaneous bortezomib was well tolerated. We have shown that functional decline, malnutrition and hospitalization at home unit are predictors of OS. These results lead us to reflect on the need to include these factors in the choice of treatment in elderly patients with MM.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"183 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2016-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74621478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-04-06DOI: 10.4172/2329-6771.1000163
Qian-ming Cheng, Yi Wen, Zhi-jian Sun, Yanyan Zhang, Xiaoxiao Qian, Jianguo Wu, C. Miao, Dongsheng Xu
Purpose: Recently, higher expression of chemokine receptors in patients with various cancer types has been observed and indicated to have prognostic significance in the clinical progression of cancers. Former research has determined that CXCR7, as a member of chemokine receptor C-X-C family, empowers greater affinity with chemokine CXCL12 than CXCR4. The present study investigated the correlation of clinical characteristics and CXCR7 expression in cancers using meta-analysis. Methods: A comprehensive search on Pubmed and Web of Science identified CXCR7-related clinical studies. Methodological quality of these studies was evaluated and all the data were extracted, calculated and analyzed. This meta-analysis was carried out with Stata 12.0. Results: Fifteen eligible studies consisting of 1780 participants were included. The results showed that CXCR7 significantly relates to tumor occurrence (pooled RR=3.12, 95% CI: 1.71-5.70, P=0.000), tumor grades (pooled RR=1.41, 95% CI: 1.14-1.75, P=0.002), tumor stages (pooled RR=1.51, 95% CI: 1.26-1.82, P=0.000) and lymph node metastasis (pooled RR=1.49, 95% CI: 1.14-1.94, P=0.000), respectively. Conclusion: Highly expressed chemokine receptor CXCR7 potentially increases tumor occurrence risk. Higher CXCR7 expression is associated with poorer prognosis, advanced stages, differentiation grades and poor lymph node metastasis in patients with various cancers. Thus, highly expressed CXCR7 could be a potential biomarker in the prognosis of cancers.
{"title":"Meta-analysis of CXCR7 Expression Related to Clinical Prognosis inCancers","authors":"Qian-ming Cheng, Yi Wen, Zhi-jian Sun, Yanyan Zhang, Xiaoxiao Qian, Jianguo Wu, C. Miao, Dongsheng Xu","doi":"10.4172/2329-6771.1000163","DOIUrl":"https://doi.org/10.4172/2329-6771.1000163","url":null,"abstract":"Purpose: Recently, higher expression of chemokine receptors in patients with various cancer types has been observed and indicated to have prognostic significance in the clinical progression of cancers. Former research has determined that CXCR7, as a member of chemokine receptor C-X-C family, empowers greater affinity with chemokine CXCL12 than CXCR4. The present study investigated the correlation of clinical characteristics and CXCR7 expression in cancers using meta-analysis. Methods: A comprehensive search on Pubmed and Web of Science identified CXCR7-related clinical studies. Methodological quality of these studies was evaluated and all the data were extracted, calculated and analyzed. This meta-analysis was carried out with Stata 12.0. Results: Fifteen eligible studies consisting of 1780 participants were included. The results showed that CXCR7 significantly relates to tumor occurrence (pooled RR=3.12, 95% CI: 1.71-5.70, P=0.000), tumor grades (pooled RR=1.41, 95% CI: 1.14-1.75, P=0.002), tumor stages (pooled RR=1.51, 95% CI: 1.26-1.82, P=0.000) and lymph node metastasis (pooled RR=1.49, 95% CI: 1.14-1.94, P=0.000), respectively. Conclusion: Highly expressed chemokine receptor CXCR7 potentially increases tumor occurrence risk. Higher CXCR7 expression is associated with poorer prognosis, advanced stages, differentiation grades and poor lymph node metastasis in patients with various cancers. Thus, highly expressed CXCR7 could be a potential biomarker in the prognosis of cancers.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"119 5 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2016-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88751366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-03-08DOI: 10.4172/2329-6771.1000161
G. Maccauro, A. Piccioli, S. Barreca, D. Fenga, M. Rosa
Patients with a solitary bone metastasis have a different prognosis according to primary tumor histotype. Surgeon has to consider this parameter when performing operations. A good prognosis means a long survivorship, high functional demands, long lasting treatment and, overall, a quick rehabilitation program. The study is on 36 patients with solitary bone metastasis from different Histotypes (Breast cancer, Kidney Cancer and Thyroid Cancer) which have been treated by resection and prostheses. Clinical findings demonstrated that resections and prosthetic reconstructions are the gold standard to help surgeon to obtain the best results. Adjuvant systemic or local therapy may help when feasible.
{"title":"Local Resections and Prosthetic Reconstructions in Solitary Bone Metastases of the Limbs According to Histotypes","authors":"G. Maccauro, A. Piccioli, S. Barreca, D. Fenga, M. Rosa","doi":"10.4172/2329-6771.1000161","DOIUrl":"https://doi.org/10.4172/2329-6771.1000161","url":null,"abstract":"Patients with a solitary bone metastasis have a different prognosis according to primary tumor histotype. Surgeon has to consider this parameter when performing operations. A good prognosis means a long survivorship, high functional demands, long lasting treatment and, overall, a quick rehabilitation program. The study is on 36 patients with solitary bone metastasis from different Histotypes (Breast cancer, Kidney Cancer and Thyroid Cancer) which have been treated by resection and prostheses. Clinical findings demonstrated that resections and prosthetic reconstructions are the gold standard to help surgeon to obtain the best results. Adjuvant systemic or local therapy may help when feasible.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77457559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-03-07DOI: 10.4172/2329-6771.1000160
S. Barreca, D. Fenga, F. Campo, M. Rosa
Sarcomas of the foot are conventionally treated with amputation. However, limb salvage procedures are possible in cases of specific histological patterns. We report a rare case of a huge myxoid liposarcoma of the dorsal and plantar aspect of the forefoot. A 47 years-old woman was admitted to our Institution complaining of a painless huge mass of the dorsal and plantar aspect of the left forefoot. Following the patient’s medical history remarking a previous myxoid liposarcoma, this finding was interpreted as a local recurrence. The mass was explored through radiographic, magnetic resonance imaging and bone scan assessments. An incisional biopsy was performed, and a myxoid liposarcoma was ultimately diagnosed. A limb salvage procedure was performed in association with coverage plastic surgery. Postoperative stay was uneventfully. Forty days after surgery the patient underwent a cycle of radiotherapy. At 10 year follow-up the patient had a good functionality without signs of local recurrence nor metastatic spread.
{"title":"Huge Liposarcoma of the Forefoot: A Case Report","authors":"S. Barreca, D. Fenga, F. Campo, M. Rosa","doi":"10.4172/2329-6771.1000160","DOIUrl":"https://doi.org/10.4172/2329-6771.1000160","url":null,"abstract":"Sarcomas of the foot are conventionally treated with amputation. However, limb salvage procedures are possible in cases of specific histological patterns. We report a rare case of a huge myxoid liposarcoma of the dorsal and plantar aspect of the forefoot. \u0000A 47 years-old woman was admitted to our Institution complaining of a painless huge mass of the dorsal and plantar aspect of the left forefoot. Following the patient’s medical history remarking a previous myxoid liposarcoma, this finding was interpreted as a local recurrence. The mass was explored through radiographic, magnetic resonance imaging and bone scan assessments. An incisional biopsy was performed, and a myxoid liposarcoma was ultimately diagnosed. \u0000A limb salvage procedure was performed in association with coverage plastic surgery. Postoperative stay was uneventfully. Forty days after surgery the patient underwent a cycle of radiotherapy. At 10 year follow-up the patient had a good functionality without signs of local recurrence nor metastatic spread.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"184 6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81057568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：